Manager TitleAgeSince
President - 30/07/2025
Compliance Officer - -
Chief Tech/Sci/R&D Officer - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.12%+2.57% - - 1.8B
+0.15%+1.21%+48.79%+97.65% 1,014B
+0.03%+0.07%+51.47%+65.55% 644B
-0.20%+4.62%+21.39%+72.57% 464B
-1.43%+3.82%+37.75%+39.06% 354B
+0.46%+2.51%+19.03%+24.93% 265B
+0.96%+4.34%+7.65%+14.35% 253B
+0.19%-3.81%+37.81%+44.35% 203B
+0.14%-4.30%-25.85%-57.88% 186B
+0.94%+1.39%+33.21%+95.16% 183B
Average +0.41%+0.96%+25.69%+43.97% 396.31B
Weighted average by Cap. +0.22%+1.41%+34.16%+60.18%
Logo Endo, Inc.
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
Employees
3,116
  1. Stock Market
  2. Stocks
  3. NDOI Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!